Balanced news tone
News Sentiment
I1NC34 sentiment intelligence
Incyte Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
13 relevant articles
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-7.0% over one week, +5.3% over four weeks, trend inactive, and materially above fair value.
Incyte Stock: Is INCY Outperforming the Healthcare Sector?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
84/100 classification
One-week reaction
-7.0%
Price reacting lower
Trend fit
Trend inactive
5.3% over four weeks
Fair value
27.5%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
10
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Barchart.com
Direct company coverage
Incyte Stock: Is INCY Outperforming the Healthcare Sector?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 09:33
- Source
- Barchart.com
MoneyCheck
Direct company coverage
Incyte (INCY) Stock Dips Despite Japan Greenlight for Minjuvi in DLBCL Treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 08:57
- Source
- MoneyCheck
Traders Union
Direct company coverage
Incyte stock drops 6.04% despite new antibody data in myelofibrosis, Incyte reports
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 05:25
- Source
- Traders Union
Investing.com South Africa
Direct company coverage
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal By Investing.com
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 10 Jun 2026 07:00
- Source
- Investing.com South Africa
Market source
Direct company coverage
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
Barchart.com
Direct company coverage
Is Incyte Stock Outperforming the Dow?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Mar 2026 07:00
- Source
- Barchart.com
IndexBox
Direct company coverage
Incyte (INCY) Stock Analysis: 6-Month Surge & Financial Health - News and Statistics
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- IndexBox
Investing.com
Direct company coverage
Incyte’s tafasitamab meets primary endpoint in frontMIND trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jan 2026 08:00
- Source
- Investing.com
GuruFocus
Direct company coverage
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitil
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Dec 2025 08:00
- Source
- GuruFocus
Clinical Trials Arena
Direct company coverage
Incyte stock hit by 11% despite paediatric dermatology trials hitting target
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 17 Mar 2025 07:00
- Source
- Clinical Trials Arena
StockInvest.us
Direct company coverage
Incyte Stock Price Forecast. Should You Buy INCY?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 01 Dec 2020 17:57
- Source
- StockInvest.us
GuruFocus
Direct company coverage
Incyte Corp (INCY) DCF Valuation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2019 05:07
- Source
- GuruFocus
C&EN
Direct company coverage
Merck, Incyte IDO inhibitor fails late-stage trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2018 07:00
- Source
- C&EN